This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/wikipedia/
n23http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/pubchem-compound/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/kegg-drug/
n19http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01176/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01176
rdf:type
n3:Drug
n3:description
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
n3:dosage
n4:271B4F29-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
20 hours
n3:indication
For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems).
owl:sameAs
n22:DB01176 n23:DB01176
dcterms:title
Cyclizine
adms:identifier
n6:3994 n7:6470 n9:46506232 n10:Cyclizine n11:6726 n12:C06930 n13:PA164742937 n14:D03621 n18:DB01176
n3:mechanismOfAction
Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of cyclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since cyclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.
n3:synonym
1-Benzhydryl-4-methylpiperazin Cyclizine Cyclizinum (N-Benzhydryl)(n'-methyl)diethylenediamine N-Benzhydryl-N'-methylpiperazine (±)-1-diphenylmethyl-4-methylpiperazine N-methyl-N'-benzhydrylpiperazine 1-(Diphenylmethyl)-4-methylpiperazine (+-)-1-Diphenylmethyl-4-methylpiperazine Ciclizina
n3:foodInteraction
Take without regard to meals. Food may reduce irritation. Avoid alcohol.
n3:salt
n3:synthesisReference
Baltzly, R. and Castillo, J.C.; U.S. Patent 2,630,435; March 3,1953; assigned to Burroughs Wellcome & Co. (U.S.A.) Inc.
n19:hasConcept
n20:M0005457
foaf:page
n25:cyclizine.html
n3:IUPAC-Name
n8:271B4F2E-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B4F34-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B4F33-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B4F30-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B4F31-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B4F32-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B4F43-363D-11E5-9242-09173F13E4C5 n8:271B4F2C-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B4F45-363D-11E5-9242-09173F13E4C5 n8:271B4F2A-363D-11E5-9242-09173F13E4C5 n8:271B4F2D-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B4F2B-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:R06AE03
n3:H-Bond-Acceptor-Count
n8:271B4F3A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B4F3B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B4F35-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B4F36-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B4F38-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B4F37-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B4F39-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82-92-8
n3:category
n3:Bioavailability
n8:271B4F3F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B4F41-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B4F42-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B4F44-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B4F3E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B4F3D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B4F40-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B4F2F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B4F3C-363D-11E5-9242-09173F13E4C5